Olaparib (Lynparza®) monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/09/2018|
|Rapid review completed||01/10/2018|
|Rapid Review outcome||The NCPE recommend a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||16/10/2018|
|Pre-submission consultation with Applicant||26/11/2018|
|Submission received from Applicant||28/06/2019|
|Preliminary review sent to Applicant||30/09/2019|
|NCPE assessment re-commenced||25/10/2019|
|Factual accuracy sent to Applicant||02/12/2019|
|NCPE assessment re-commenced||12/12/2019|
|NCPE assessment completed||04/02/2020|
|NCPE assessment outcome||The NCPE recommends that olaparib (Lynparza®), for this indication, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.